The sixth meeting on Cancer Collaboration is arranged on 13th March at Medicon Village in collaboration with Lund University Cancer Center (LUCC), LU Innovation, Medicon Village, SmiLe Incubator, BBMRI.se and Medicon Valley Alliance.
You’re invited to interact around research and innovation in the oncology area. How can new ideas be created by working cross borders? How can industry, academia and healthcare sector work together?
Please register no later than 4th March. SIGN UP HERE
- MORNING SESSION, The Auditorium, Medicon Village
08.45 Welcome and introduction
09.05 -10.10 Keynote session:
"Endocrine FGFs; from Basic Mechanisms to Therapeutic Opportunities"
Professor Joseph P. Schlessinger, Yale University.
10.25 - 11.25 Catwalk pitch:
Companies and researchers enter the stage pitching their ideas and inviting people to collaborate
11.30 - 12.30 Speed networking:
Your opportunity to get to know other colleagues involved in cancer research and make new cross border connections to ensure fruitful future collaborations
- LUNCH SESSION, Restaurant Inspira, Medicon Village
12.30 – 13.00 Lunch
13.00 - 13.30 Inspirational lecture:
“Cancerland tur och retur” (in Swedish)
MD Karin Wahlberg
13.30 Summary, End of meeting
- AFTERNOON SESSION, closed session
13.30 - 15.30 Dialogue forum – closed sessions. Including coffee.
The Dialogue forums, held after lunch as closed sessions, will give companies and academic researchers a unique opportunity to discuss specific questions related to commercialization of research findings.
If you have questions or topics you’d like to bring up for the Dialogue forums, please contact: firstname.lastname@example.org.
- Joseph P Schlessinger, PhD, Professor at Yale University, New Haven, Connecticut
Professor Schlessinger is a pioneer within the area of growth factor signalling and has published numerous articles in the area of the FGF-receptor and its mechanism of activation and signaling, but also work relating to growth factor receptors, such as the EGFR and KIT. He is among the most highly cited scientists within this field of research. Professor Schlessinger has also been co-founder in several biotech companies. Among those, SUGEN (now part of Pfizer; was one of the first companies to develop several targeted tyrosine kinase inhibitors for cancer treatment), Plexxikon (now part of Daiichi-Sankyo, developed the first BRAF inhibitor for treatment of malignant melanoma) and Kolltan Pharmaceuticals that develops therapeutic antibodies against receptor tyrosine kinases.
- Karin Wahlberg, MD Specialist in Gynecology
MD Karin Wahlberg, specialist in Gynecology and well known author who describe “health care from the inside” in her detective stories. Karin has as well shared her own experiences of being a patient in one of the books. Karin will present in Swedish.
The event is sponsored by BioCARE, LU Innovation, SmiLe Incubator and Medicon Village